1. Home
  2. SPPL vs CODX Comparison

SPPL vs CODX Comparison

Compare SPPL & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPPL

SIMPPLE LTD.

HOLD

Current Price

$4.21

Market Cap

19.5M

Sector

N/A

ML Signal

HOLD

Logo Co-Diagnostics Inc.

CODX

Co-Diagnostics Inc.

HOLD

Current Price

$0.39

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPPL
CODX
Founded
2016
2013
Country
Singapore
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.5M
15.6M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
SPPL
CODX
Price
$4.21
$0.39
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.25
AVG Volume (30 Days)
3.5K
2.1M
Earning Date
01-01-0001
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,591,508.00
$507,892.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$31.58
P/E Ratio
N/A
N/A
Revenue Growth
24.27
N/A
52 Week Low
$2.18
$0.23
52 Week High
$16.80
$1.55

Technical Indicators

Market Signals
Indicator
SPPL
CODX
Relative Strength Index (RSI) 47.10 52.37
Support Level $3.49 $0.34
Resistance Level $4.75 $0.42
Average True Range (ATR) 0.23 0.04
MACD 0.04 0.00
Stochastic Oscillator 57.85 84.37

Price Performance

Historical Comparison
SPPL
CODX

About SPPL SIMPPLE LTD.

Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.

About CODX Co-Diagnostics Inc.

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

Share on Social Networks: